Keith Dionne, Ph.D.
Chief Executive Officer
Keith Dionne is an industry veteran with 20+ years of experience leading U.S. and international biotechnology companies. Most recently, he was president and CEO of Constellation Pharmaceuticals – an oncology focused epigenetics company.
Prior to joining Constellation, he was an entrepreneur-in-residence at Third Rock Ventures. Before that, he served as the CEO at Surface Logix, Inc. which was acquired by Nano Terra, Inc. Keith was the president and CEO of Alantos Pharmaceuticals, leading the company’s acquisition by Amgen for more than $300 million in 2007. Prior to joining Alantos, Keith was with Millennium Pharmaceuticals (now Takeda) where he held positions of increasing responsibility, concluding his seven-year tenure as vice president of business development and general manager, technology business. Prior to Millennium, Keith led implantable drug delivery research at ALZA Pharmaceuticals where he spearheaded the development of Viadur™, a 12-month implantable treatment for prostate cancer. He was one of four original scientists at CytoTherapeutics, a cell transplantation company. Keith has also served as an adjunct professor in the biomedical department at Brown University.
Keith received both his Ph.D. in chemical engineering and his M.S. in the program for technology policy from the Massachusetts Institute of Technology. He is an assistant wrestling coach at Belmont High school, where his son Max wrestles at 145 lbs.
Why Casma, Why Me?
I am excited to be part of Casma’s efforts to develop novel therapeutics to enhance autophagy in order to cure serious and widespread diseases such as lysosomal storage disorders and neurodegeneration. Casma is attracting a diverse and intelligent group of people who share the value of creating cures for difficult diseases. We are building a culture of trust, risk taking and teamwork. This fits what I want to do with my life.